Generic Bromday Availability
BROMDAY (bromfenac sodium - solution/drops;ophthalmic)
Manufacturer: BAUSCH AND LOMB INC
Approval date: October 16, 2010
Strength(s): EQ 0.09% ACID [RLD] [AT]
Has a generic version of Bromday been approved?
A generic version of Bromday has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Bromday and have been approved by the FDA:
Manufacturer: APOTEX INC
Approval date: June 23, 2014
Strength(s): EQ 0.09% ACID [AT]
Manufacturer: HI-TECH PHARMACAL
Approval date: January 22, 2014
Strength(s): EQ 0.09% ACID [AT]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bromday. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Bromday.
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 16, 2013 -
- Bromday Consumer Information (Drugs.com)
- Bromday Consumer Information (Wolters Kluwer)
- Bromday ophthalmic Consumer Information (Cerner Multum)
- Bromday Advanced Consumer Information (Micromedex®)
- Bromfenac Consumer Information (Wolters Kluwer)
- Bromfenac ophthalmic Consumer Information (Cerner Multum)
- Bromfenac Ophthalmic Advanced Consumer Information (Micromedex®)
- Bromfenac Sodium AHFS DI Monographs (ASHP)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|
|AT||Topical products. There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products containing the same active ingredient in the same topical dosage form for which a waiver of in vivo bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded AT. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded AB when supported by adequate bioequivalence data, and BT in the absence of such data.|